

the meeting. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to five minutes per speaker. Individuals who would like to submit written statements should e-mail or fax their comments to the National Vaccine Program Office at least five business days prior to the meeting. Those wishing to register to attend the meeting may do so by sending an e-mail to nvpo@hhs.gov or by calling 202-690-5566 and providing name, e-mail address and organization.

Dated: August 23, 2010.

Bruce Gellin,

Deputy Assistant Secretary for Health, Director, National Vaccine Program Office.

[FR Doc. 2010-21263 Filed 8-25-10; 8:45 am]

BILLING CODE 4150-44-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Meeting of the Presidential Commission for the Study of Bioethical Issues

AGENCY: Department of Health and Human Services, Office of Public Health and Science, The Presidential Commission for the Study of Bioethical Issues.

ACTION: Notice of meeting.

SUMMARY: The Presidential Commission for the Study of Bioethical Issues will conduct a meeting in September. At this meeting, the Commission will continue discussing the emerging science of synthetic biology, including its potential benefits and risks, and appropriate ethical boundaries and principles.

DATES: The meeting will take place Monday, September 13, 2010, from 8:50 a.m. to approximately 4:15 p.m., and Tuesday, September 14, 2010, from 9 a.m. to approximately noon.

ADDRESSES: Monday, September 13, The Inn at Penn, 3600 Sansom Street, Philadelphia, PA 19104. Phone 215-222-0200. Tuesday, September 14, The Annenberg Public Policy Center, 202 South 36th Street, Philadelphia, PA 19104. Phone 215-898-9400.

FOR FURTHER INFORMATION CONTACT: Ms. Diane M. Gianelli, Director of Communications, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue, NW., Suite C-100, Washington, DC 20005. Telephone: 202/233-3960. E-mail: info@bioethics.gov. Additional information may be obtained by viewing the Web site: <http://www.bioethics.gov>.

SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee Act,

Public Law 92-463, 5 U.S.C. App., notice is hereby given that the Presidential Commission for the Study of Bioethical Issues (PCSBI) will be conducting a meeting. The meeting will be held from 8:50 a.m. to approximately 4:15 p.m. on Monday, September 13, 2010, at the Inn at Penn, 3600 Sansom Street, Philadelphia, PA 19104, and from 9 a.m. to approximately noon on Tuesday, September 14, 2010, at The Annenberg Public Policy Center, 202 South 36th Street, Philadelphia, PA 19104. The meeting will be open to the public with attendance limited to space available. The meeting will also be Web cast.

Under authority of Executive Order 13521, dated November 24, 2009, the President established the PCSBI to serve as a public forum and advise him on bioethical issues generated by novel and emerging research in biomedicine and related areas of science and technology. The Commission is charged to identify and promote policies and practices that assure ethically responsible conduct of scientific research, healthcare delivery, and technological innovation. In undertaking these duties, the Commission will examine specific bioethical, legal, and social issues related to potential scientific and technological advances; examine diverse perspectives and possibilities for useful international collaboration on these issues, and recommend legal, regulatory, or policy actions as appropriate. The main agenda items for this meeting involve further discussion of the opportunities and benefits to the public of the emerging science of synthetic biology, the challenges and risks, and the ethical boundaries that may be important to formulation of public policy with regard to this advancing science. The Commission also will hear more from the perspective of faith communities and others. The draft meeting agenda and other information about PCSBI, including information about access to the Web cast, will be available at <http://www.bioethics.gov>.

The Commission welcomes input from anyone wishing to provide public comment on any issue before it. Individuals who would like to provide public comment at the meeting should notify Ms. Diane Gianelli, Director of Communications, by telephone at 202-233-3960, or e-mail at diane.gianelli@bioethics.gov. Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should also notify Ms. Gianelli in advance of the meeting. The Commission will make

every effort to accommodate persons who need special assistance.

Written comments will also be accepted in accord with the Commission's existing request for public comment on the issues before the Commission. Please address written comments by e-mail to info@bioethics.gov, or by mail to the following address: Public Commentary, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave., NW., Suite C-100, Washington, DC 20005. Comments will be publicly available, including any personally identifiable or confidential business information that they contain. Trade secrets should not be submitted.

Dated: August 17, 2010.

Valerie H. Bonham,

Executive Director, The Presidential Commission for the Study of Bioethical Issues.

[FR Doc. 2010-21267 Filed 8-25-10; 8:45 am]

BILLING CODE 4154-06-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Proposed Collection: Comment Request

In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Pub. L. 104-13), the Health Resources and Services Administration (HRSA) publishes periodic summaries of proposed projects being developed for submission to the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, e-mail paperwork@hrsa.gov or call the HRSA Reports Clearance Officer at (301) 443-1129.

Comments are invited on: (a) The proposed collection of information for the proper performance of the functions of the agency; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Sickle Cell Disease and Other Hemoglobinopathies Program Evaluation—[NEW]

Background: In response to the growing need for resources devoted to sickle cell disease and other hemoglobinopathies, Congress, under Section 501(a)2 of the Social Security Act (2000), authorized the appropriation of funds for enabling the Secretary to provide for special projects of regional and national significance, research and training with respect to maternal and child health and children with special health care needs the following: Genetic disease testing, counseling and information development and dissemination programs, for grants relating to hemophilia without regard to age, and for the screening of newborns for sickle cell anemia and other genetic disorders, and follow-up services. As stated in House Report No. 107–229 regarding the Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill 2002, the purpose of the Sickle Cell Disease and Newborn Screening Program (SCDNBSP) is “to enhance the sickle cell disease newborn screening program and its locally based outreach and counseling efforts.” In addition, the American Jobs Creation Act of 2004, Public Law 108–357, states that “* * * the Bureau of Primary Health Care and the Maternal and Child Health Bureau, shall conduct a demonstration program by making grants for up to 40 eligible entities, for each fiscal year in which the program is conducted under this section, for the purpose of developing and establishing systemic mechanisms to improve the

prevention and treatment of Sickle Cell Disease.” (See 42 U.S.C. 300b–1).

Purpose: HRSA’s activities under the legislative authorities relative to the Sickle Cell Disease and Newborn Screening Program (SCDNBSP) have been delegated to the Maternal and Child Health Bureau (MCHB), Genetic Services Branch (GSB). The MCHB’s GSB supports seventeen community based organizations and the National Coordinating and Evaluation Center for the Sickle Cell Disease and Newborn Screening Program (SCDNBS) in addition to nine cooperative agreements and a National Coordinating Center for the Sickle Cell Disease Treatment Demonstration Program (SCDTDP). An evaluation will be conducted to assess the service delivery processes and quality of the system of care delivered by grantees under the Newborn Screening Program to individuals affected by Sickle Cell disease who present at their sites for care. The Centers for Disease Control and Prevention defines Hemoglobinopathies as “a group of disorders affecting red blood cells. SCD and Thalassemia are included in this group.” (See http://www.cdc.gov/ncbddd/sicklecell/RuSH_FAQs.html). The information from the evaluation will be used to evaluate the grantees’ performance in achieving the objectives of the hemoglobinopathies program during the grant period, assess the breadth of grantees’ outreach to emerging populations affected by hemoglobinopathies and the needs of those populations attempting to access services. Data collection tools for which OMB approval is being requested are as

follows: (1) The Minimum Database Project Sickle Cell Disease (MDP SCD) Questionnaire, (2) the Minimum Database Project Sickle Cell Trait/Carrier (MDP SCT) Questionnaire, and (3) the MDP Hemoglobinopathies Emerging Populations Questionnaire.

Respondents: The MDP SCD and the MDP SCT Questionnaires will be administered by grantees to clients or caregivers when they present for services. At the time of enrollment, SCDNBSP participants will be informed about the data collection and clients will be asked to participate in either the SCD questionnaire or the SCT questionnaire depending on their disease or carrier status. The program will enroll participants on a rolling basis such that new patients will be added to the program as they present for services and provide consent. Data will be collected at two points annually for the SCD Questionnaire, the first, when clients and caregivers are enrolled into the SCDNBS Program and the second, at follow-up after enrollment. Data will be collected once annually for the SCT Questionnaire. The Hemoglobinopathies Emerging Populations Form serves as a stand alone form for the other HRSA hemoglobinopathies programs, with its content. These questions are also embedded in the MDT SCD and MDP SCT questionnaires. The HRSA hemoglobinopathies programs also plan to use this questionnaire in developing educational materials, prioritizing outreach activities and informing decisions for future funding requests.

The annual estimate of burden is as follows:

Questionnaires	Number of respondents	Responses per respondent	Total responses	Average hours per response	Total hour burden	Wage rate	Total hour cost
MDP SCD Questionnaire	140	2	280	.45	126	\$20.90	\$2,633.40
MDP SCT Questionnaire	1,400	1	1,400	.30	420	20.90	8,778.00
Hemoglobinopathies Emerging Populations Form	*1,125	2	*2,250	.20	450	20.90	9,405.00
Total	2,665	3,930	996	20,816.40

E-mail comments to paperwork@hrsa.gov or mail the HRSA Reports Clearance Officer, Room 10–33, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: August 19, 2010.
Sahira Rafiullah,
Director, Division of Policy and Information Coordination.
 [FR Doc. 2010–21220 Filed 8–25–10; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0213]

Su Van Ho: Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.